NICE Rejects Akcea’s High-Cost Waylivra
Data Doubts Also An Issue
Initial knock-back from NICE means Akcea will need to improve commercial offer.
You may also be interested in...
NICE has given the green light to Akcea Therapeutics’ ultra-rare disease treatment Tegsedi (inotersen) after the company offered a better “commercial arrangement.”
The Coalition for Epidemic Preparedness Innovations adds new deal with mRNA specialist Moderna for rapid development of coronavirus vaccine.